Novartis IndiaNSE:NOVARTIND +1.93%68 Pretax Margin % is 33.29% as of Mar. 2026, which is 34% above its 10-year median of 24.76. GuruFocus rates NSE:NOVARTIND with a GF Score™ of 68/100 and a GF Value™ of ₹642.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Novartis India ranks better than 94.8% on this metric.
The historical rank and industry rank for Novartis India's Pretax Margin % or its related term are showing as below:
NSE:NOVARTIND'
s Pretax Margin % Range Over the Past 10 Years
Min: -0.99 Med: 24.76 Max: 36.77
Current: 36.59
NSE:NOVARTIND's Pretax Margin % is ranked better than 94.8% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs NSE:NOVARTIND: 36.59
Novartis India (NSE:NOVARTIND) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Novartis India Pretax Margin % Related Terms
Novartis India Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Novartis India's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NOVARTIND vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Novartis India's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (NSE:NOVARTIND) has a Pretax Margin % of 33.29% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novartis India and its competitors. This is 34% above median its historical median of 24.76. According to the industry distribution chart, Novartis India ranks #50 out of 961 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Novartis India's Pretax Margin % too high?
Novartis India's current Pretax Margin % of 33.29% is 34% above median its 10-year median of 24.76. The Drug Manufacturers industry median Pretax Margin % is 7.28. Novartis India's value of 33.29% is 357.3% above this industry median. Based on the distribution chart, Novartis India ranks #50 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis India has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #50 out of 961 companies for Pretax Margin %. This places Novartis India in the top 5% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Novartis India's value of 33.29% is 357.3% above this benchmark. While the company's 10-year median is 24.76 vs. the industry median of 7.28, Novartis India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis India's current Pretax Margin % of 33.29% is 357.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current Pretax Margin % is 33.29%, which is 34% above median its own 10-year median of 24.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (NSE:NOVARTIND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹642.38, compared to a current price of ₹1,494.60 — trading 132.7% above its estimated fair value. The current Pretax Margin % is 33.29%, which is 34% above median its 10-year median of 24.76 and 357.3% above the Drug Manufacturers industry median of 7.28. Novartis India's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Novartis India (NSE:NOVARTIND), the current Pretax Margin % is 33.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,494.60 is trading 132.7% above its estimated GF Value™ of ₹642.38.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for NSE:NOVARTIND:
Pretax Margin %: 33.29% (34% above median its 10-year median of 24.76)
GF Value™: ₹642.38 vs. price of ₹1,494.60 (132.7% above fair value)
Industry Position: 357.3% above the Drug Manufacturers median (#50 of 961)
No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
68GF Score
Get the complete analysis for NSE:NOVARTIND
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NOVARTIND has been successfully added to your 
